Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest


Narcolepsy and Idiopathic Hypersomnia
  • Educate on the burden of illness associated with narcolepsy, including cardiovascular comorbidities, cardiometabolic comorbidities and the lifelong management of the disease
  • Educate on the potential impact of sodium content on health and the relevance of this risk to narcolepsy patients
  • Educate on the screening, diagnosis, and management of idiopathic hypersomnia
  • Educate on the screening and diagnosis of narcolepsy in adults and children
  • Educate on the impact of delayed diagnosis of narcolepsy
Excessive Daytime Sleepiness in Obstructive Sleep Apnea
  • Educate on the prevalence, potential cause and differential diagnosis of EDS in OSA
  • Educate on the need to treat EDS in OSA to include:
    • Impact on cognitive function
    • Quality of life (QOL)
    • Daily functioning
    • Societal burden
  • Educate on appropriate screening tools for EDS in OSA, continued monitoring of sleepiness, and recognition of suboptimal treatment
  • Educate on pharmacotherapy options available for EDS in OSA to include:
    • Efficacy
    • Safety
    • Treatment goals
    • Impact on patient function and QOL
    Movement Disorders

    Cannabinoid Science


    Acute Myeloid Leukemia
    • Educate on the role of intensive chemotherapy in the treatment of secondary AML
    • Educate on identification and timely, actionable diagnosis of high risk AML subsets (e.g., AML-MRC, t-AML)
    • Educate on different technologies for the delivery of secondary AML treatments
      • Educate on the treatment of secondary AML to include:
        • Efficacy
        • Safety
        • Impact on QOL
        • Depth of response and real world data
    • Educate on the appropriate management of secondary AML patients in the in-patient and out-patient setting
    • Educate on the adult AML treatment paradigm (e.g., induction, consolidation, maintenance therapy)
    • Educate on clinical and economic burden of secondary AML
    • Educate on the pediatric population including relapsed/refractory AML
    Endothelial Related Complications
    • Educate on recognition, incidence, risk factors, diagnosis and early intervention of hepatic veno-occlusive disease (VOD)/ Sinusoidal Obstruction Syndrome (SOS)
    • Educate on VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
    • Educate on the pathophysiology and progressive nature of VOD/SOS and other endothelial related complications
    • Educate on the efficacy and safety of current therapies and patient management for the treatment of VOD/SOS
    • Educate on the clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
    • Educate on the efficacy of current therapies and patient management for COVID-19 related ARDS and endotheliitis
    Small Cell Lung Cancer (US and Canada Only)
    • Educate on treatment options in second-line therapy for small cell lung cancer (SCLC)
    • Educate on current second-line therapies for SCLC to include:
      • Efficacy
      • Safety
      • Mechanism of Action
    • Educate on patient management and safety profiles of SCLC second line therapies
    Acute Lymphoblastic Leukemia
    • Educate on the:
      • Biology of immune response
      • Management of asparaginase hypersensitivity reaction
      • Impact and burden on safety and efficacy
    • Educate on potential safety concerns associated with current clinical mitigation strategies for hypersensitivity reactions
    • Educate on the efficacy and clinical benefits of new asparaginase formulation in ALL
    • Educate on the management of pediatric and adult/young adult ALL with asparaginase (e.g., monitoring, PK, safety, clinical value)
    • Educate on asparaginase inspired protocols in the adult/young adult population
    • Educate on asparaginase therapies beyond ALL

    View our current requests for application.

    Eligible educational grant applicants include the following (not an exhaustive list):

    • Medical Schools
    • Medical Associations/Medical Societies
    • Hospitals/Medical Centers
    • Medical Education Providers

    This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

    In Europe & International (EUR/INT) the system is also accepting requests for medical grants as allowed by local regulations.

    The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

    How to Apply

    • Grant requests should be submitted using the Jazz Pharmaceuticals Request Management System.
    • All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
    • The system will guide applicants through the process of determining the request type and the required documents for each request.
    • Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
    • All decisions regarding support are at the discretion of Jazz and will be communicated by email.
    • Submission of a request does not guarantee support.
    • For more information, or for questions regarding the status of a grant request, please email